RNA Interference Therapeutics
Middle East · 2 shared keywords
Updated
Reviewed by Chandani Patel
Middle East Lp(a) Targeted Therapies Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$433.3 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $3.7 Mn | — | — |
| 2025 (base) | $6.0 Mn | +$2.3 Mn | — |
| 2026 (forecast) | $9.6 Mn | +$3.7 Mn | +61.2% |
| 2027 (forecast) | $15.5 Mn | +$5.9 Mn | +159.9% |
| 2028 (forecast) | $25.0 Mn | +$9.5 Mn | +318.9% |
| 2029 (forecast) | $40.4 Mn | +$15.3 Mn | +575.2% |
| 2030 (forecast) | $65.1 Mn | +$24.7 Mn | +988.5% |
| 2031 (forecast) | $104.9 Mn | +$39.8 Mn | +1,654.6% |
| 2032 (forecast) | $169.0 Mn | +$64.2 Mn | +2,728.5% |
| 2033 (forecast) | $272.5 Mn | +$103.5 Mn | +4,459.5% |
| 2034 (forecast) | $439.3 Mn | +$166.8 Mn | +7,250% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $6.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $439.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 61.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug type, indication and end user (see all) |
| Key players | Novartis AG, Amgen Inc., Eli Lilly and Company, Silence Therapeutics, Ionis Pharmaceuticals (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Lp(a) targeted therapies lower lipoprotein(a), an inherited risk factor for heart disease that current cholesterol drugs do not treat well.
Key segments of the lp(a) Targeted Therapies market include drug type (Antisense Oligonucleotides, siRNA and Oral Small Molecules) and indication (Cardiovascular Event Prevention and Aortic Valve Stenosis).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the lp(a) Targeted Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the lp(a) Targeted Therapies market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the lp(a) Targeted Therapies market. Long-term safety data and lifestyle support are still needed for many patients.
The lp(a) Targeted Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lp(a) Targeted Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.
What doctors and scientists are doing in Lp(a) Targeted Therapies right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 2 shared keywords
Middle East · 1 shared keyword
Middle East
Middle East
Middle East
Middle East
Digital Health · Middle East
Medical Devices · Middle East
Medical Devices · Middle East
Medical Devices · Middle East
Medical Devices · Middle East
Medical Devices · Middle East